AZ sells nasal spray rights to J&J
AstraZeneca is divesting certain rights to its nasal inflammation spray Rhincort Aqua to Johnson & Johnson group Cilag GmbH International.
Read More
Tag: Rhincort Aqua
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
